These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

184 related items for PubMed ID: 1674530

  • 1. N-(p-isothiocyanatophenethyl)spiperone, a selective and irreversible antagonist of D2 dopamine receptors in brain.
    Xu SX, Hatada Y, Black LE, Creese I, Sibley DR.
    J Pharmacol Exp Ther; 1991 May; 257(2):608-15. PubMed ID: 1674530
    [Abstract] [Full Text] [Related]

  • 2. Inactivation of D1 and D2 dopamine receptors by N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline in vivo: selective protection by neuroleptics.
    Meller E, Bohmaker K, Goldstein M, Friedhoff AJ.
    J Pharmacol Exp Ther; 1985 Jun; 233(3):656-62. PubMed ID: 2861276
    [Abstract] [Full Text] [Related]

  • 3. Prolonged D2 antidopaminergic activity of alkylating and nonalkylating derivatives of spiperone in rat brain.
    Baldessarini RJ, Kula NS, Campbell A, Bakthavachalam V, Yuan J, Neumeyer JL.
    Mol Pharmacol; 1992 Nov; 42(5):856-63. PubMed ID: 1435753
    [Abstract] [Full Text] [Related]

  • 4. Dopamine receptor reappearance after irreversible receptor blockade: effect of chronic estradiol treatment of ovariectomized rats.
    Lévesque D, Di Paolo T.
    Mol Pharmacol; 1991 May; 39(5):659-65. PubMed ID: 1674586
    [Abstract] [Full Text] [Related]

  • 5. Day/night differences in D1 but not D2 DA receptor protection from EEDQ denaturation in rats treated with continuous cocaine.
    Burger LY, Martin-Iverson MT.
    Synapse; 1993 Jan; 13(1):20-9. PubMed ID: 8093985
    [Abstract] [Full Text] [Related]

  • 6. Effect of chronic estradiol treatment on brain dopamine receptor reappearance after irreversible blockade: an autoradiographic study.
    Morissette M, Lévesque D, Di Paolo T.
    Mol Pharmacol; 1992 Sep; 42(3):480-8. PubMed ID: 1357544
    [Abstract] [Full Text] [Related]

  • 7. In vivo binding of SCH 39166: a D-1 selective antagonist.
    McQuade RD, Duffy RA, Coffin VL, Chipkin RE, Barnett A.
    J Pharmacol Exp Ther; 1991 Apr; 257(1):42-9. PubMed ID: 1826927
    [Abstract] [Full Text] [Related]

  • 8. In vitro and in vivo receptor binding and effects on monoamine turnover in rat brain regions of the novel antipsychotics risperidone and ocaperidone.
    Leysen JE, Janssen PM, Gommeren W, Wynants J, Pauwels PJ, Janssen PA.
    Mol Pharmacol; 1992 Mar; 41(3):494-508. PubMed ID: 1372084
    [Abstract] [Full Text] [Related]

  • 9. A comparison of the selectivities of SCH 23390 with BW737C89 for D1, D2 and 5-HT2 binding sites both in vitro and in vivo.
    Riddall DR.
    Eur J Pharmacol; 1992 Jan 21; 210(3):279-84. PubMed ID: 1351844
    [Abstract] [Full Text] [Related]

  • 10. Receptor-binding properties in vitro and in vivo of ritanserin: A very potent and long acting serotonin-S2 antagonist.
    Leysen JE, Gommeren W, Van Gompel P, Wynants J, Janssen PF, Laduron PM.
    Mol Pharmacol; 1985 Jun 21; 27(6):600-11. PubMed ID: 2860558
    [Abstract] [Full Text] [Related]

  • 11. Chronic treatment with dopamine receptor antagonists: behavioral and pharmacologic effects on D1 and D2 dopamine receptors.
    Hess EJ, Norman AB, Creese I.
    J Neurosci; 1988 Jul 21; 8(7):2361-70. PubMed ID: 2907912
    [Abstract] [Full Text] [Related]

  • 12. Effects of in vivo and in vitro treatments with N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline on putative muscarinic receptor subtypes in rat brain.
    Norman AB, Creese I.
    Mol Pharmacol; 1986 Aug 21; 30(2):96-103. PubMed ID: 3755499
    [Abstract] [Full Text] [Related]

  • 13. Agonist-induced desensitization of D2 dopamine receptors in human Y-79 retinoblastoma cells.
    Barton AC, Black LE, Sibley DR.
    Mol Pharmacol; 1991 May 21; 39(5):650-8. PubMed ID: 1674585
    [Abstract] [Full Text] [Related]

  • 14. [3H]-quinelorane binds to D2 and D3 dopamine receptors in the rat brain.
    Gackenheimer SL, Schaus JM, Gehlert DR.
    J Pharmacol Exp Ther; 1995 Sep 21; 274(3):1558-65. PubMed ID: 7562534
    [Abstract] [Full Text] [Related]

  • 15. Dopamine displaces [3H]domperidone from high-affinity sites of the dopamine D2 receptor, but not [3H]raclopride or [3H]spiperone in isotonic medium: Implications for human positron emission tomography.
    Seeman P, Tallerico T, Ko F.
    Synapse; 2003 Sep 15; 49(4):209-15. PubMed ID: 12827639
    [Abstract] [Full Text] [Related]

  • 16. Acute in vivo amphetamine produces a homologous desensitization of dopamine receptor-coupled adenylate cyclase activities and decreases agonist binding to the D1 site.
    Roseboom PH, Gnegy ME.
    Mol Pharmacol; 1989 Jan 15; 35(1):139-47. PubMed ID: 2563306
    [Abstract] [Full Text] [Related]

  • 17. Selective alkylatation of dopamine D2 and D4 receptors in rat brain by N-(p-isothiocyanatophenethyl)spiperone.
    Zhang K, Tarazi FI, Kula NS, Baldessarini RJ, Neumeyer JL.
    Neurosci Lett; 1999 Oct 29; 274(3):155-8. PubMed ID: 10548413
    [Abstract] [Full Text] [Related]

  • 18. Age-dependent differences in the rate of recovery of striatal dopamine D1 and D2 receptors after inactivation with EEDQ.
    Crawford CA, Rowlett JK, McDougall SA, Bardo MT.
    Eur J Pharmacol; 1994 Feb 03; 252(2):225-31. PubMed ID: 8157063
    [Abstract] [Full Text] [Related]

  • 19. Anatomical localization of SKF-38393-induced behaviors in rats using the irreversible monoamine receptor antagonist EEDQ.
    Neisewander JL, Ong A, McGonigle P.
    Synapse; 1995 Feb 03; 19(2):134-43. PubMed ID: 7725242
    [Abstract] [Full Text] [Related]

  • 20. Differential modification of striatal D1 dopamine receptors and effector moieties by N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline in vivo and in vitro.
    Hess EJ, Battaglia G, Norman AB, Creese I.
    Mol Pharmacol; 1987 Jan 03; 31(1):50-7. PubMed ID: 3100940
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.